D-Isoascorbic Acid and Arsenic Trioxide Therapy in KRAS-Mutant Metastatic Colorectal Cancer: A Case Report and Focused Review

Background: D-isoascorbic acid (D-VC), also known as erythorbic acid, and arsenic trioxide (ATO) have shown antitumour effects in preclinical models of KRAS-mutant colorectal cancer (CRC); however, clinical evidence in refractory disease is limited. Case Presentation: A 43-year-old man with heavily pretreated, microsatellite-stable (MSS) metastatic CRC underwent treatment with ATO and D-VC. Serial CT examinations showed little interval change in the dimensions of two selected pulmonary metastatic lesions between December 2023 and February 2024. However, following the initial courses of D-VC in combination with ATO in 2023, radiological progression was documented on 2 July 2024, before D-VC monotherapy was reintroduced and the dose was subsequently escalated. Next-generation sequencing of the primary tumour, followed by expert variant annotation, identified a complex genomic profile, including concurrent somatic KRAS p.Gly12Cys and PIK3CA p.Glu542Lys alterations. A PRKN p.Arg275Trp variant was also annotated as potentially germline in origin; however, its constitutional status could not be independently confirmed because matched non-tumour DNA was unavailable. The potential implications of this variant for mitophagy and mitochondrial quality control remain hypothetical. Conclusions: This single-patient observation does not establish clinical efficacy or predictive biomarkers for ATO/D-VC therapy. It illustrates the complementary information of tumour molecular profiling and clinical observations in characterising refractory CRC and underscores the importance of appropriate germline assessment when potentially germline variants are identified. Prospective clinical studies and functional investigations are required to clarify the molecular determinants of response and resistance to the ATO/D-VC combination.

Authors

Institutions

Publication Details

Journal
Biomedicines
Published
2026-11-20
DOI
https://doi.org/10.3390/biomedicines14112696
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

D-Isoascorbic Acid and Arsenic Trioxide Therapy in KRAS-Mutant Metastatic Colorectal Cancer: A Case Report and Focused Review

Ainur R. Akilzhanova, Akbota M. Aitkulova, Bakytgul Yermekbayeva, Dos D. Sarbassov et al.
Biomedicines
Colorectal Cancer Treatments and Studies
article

D-Isoascorbic Acid and Arsenic Trioxide Therapy in KRAS-Mutant Metastatic Colorectal Cancer: A Case Report and Focused Review

Ainur R. Akilzhanova, Akbota M. Aitkulova, Bakytgul Yermekbayeva, Dos D. Sarbassov, Diana Samatkyzy, Nuray Tynyshtykbayeva
article en

Abstract

Background: D-isoascorbic acid (D-VC), also known as erythorbic acid, and arsenic trioxide (ATO) have shown antitumour effects in preclinical models of KRAS-mutant colorectal cancer (CRC); however, clinical evidence in refractory disease is limited. Case Presentation: A 43-year-old man with heavily pretreated, microsatellite-stable (MSS) metastatic CRC underwent treatment with ATO and D-VC. Serial CT examinations showed little interval change in the dimensions of two selected pulmonary metastatic lesions between December 2023 and February 2024. However, following the initial courses of D-VC in combination with ATO in 2023, radiological progression was documented on 2 July 2024, before D-VC monotherapy was reintroduced and the dose was subsequently escalated. Next-generation sequencing of the primary tumour, followed by expert variant annotation, identified a complex genomic profile, including concurrent somatic KRAS p.Gly12Cys and PIK3CA p.Glu542Lys alterations. A PRKN p.Arg275Trp variant was also annotated as potentially germline in origin; however, its constitutional status could not be independently confirmed because matched non-tumour DNA was unavailable. The potential implications of this variant for mitophagy and mitochondrial quality control remain hypothetical. Conclusions: This single-patient observation does not establish clinical efficacy or predictive biomarkers for ATO/D-VC therapy. It illustrates the complementary information of tumour molecular profiling and clinical observations in characterising refractory CRC and underscores the importance of appropriate germline assessment when potentially germline variants are identified. Prospective clinical studies and functional investigations are required to clarify the molecular determinants of response and resistance to the ATO/D-VC combination.

BiomedicinesVol. 14(11)
Nazarbayev University (KZ)
Ministry of Science and Higher Education of the Republic of Kazakhstan
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon